Clinical efficacy of simvastatin with different doses combined with fenofibrate in treatment of type 2 diabetes complicated with hyperlipidemia

Objective To investigate the clinical efficacy and safety of simvastatin with different doses combined with fenofibrate in treatment of type 2 diabetes complicated with hyperlipidemia. Methods Patientswith type 2 diabetes complicated with hyperlipidemia from June 2010 to April 2014(110 cases) were randomly divided into high dose and low dose groups(n = 55). Patients in two groups were po administered with Fenofibrate Capsules, 1 grain/time, three times daily. Patients in high dose group were po administered with Simvastatin Tablets, 40 mg/time, once daily, while patients in low dose group were po administered with Simvastatin Tablets, 20 mg/time, once daily. The patients in the two groups were treated for 8 weeks. The levels of blood lipid, indexes of blood safety and incidence of adverse reactions in two groups were compared. Results After treatment, levels of blood lipid in two groups were improved significantly, and TC, TG, and LDL-C were significantly reduced, while HDL-C was significantly higher, and the difference was statistically significant before and after the treatment in the same group(P 0.05). After treatment, ALT, BUN, and Cr of high dose group were significantly higher, while BUN of low dose group was lower and Cr was higher, and the difference was statistically significant before and after the treatment in the same group(P 0.05). After treatment, ALT, BUN, and Cr in low dose group were lower than those in the high dose group, and there were differences between the two groups(P 0.05, 0.01). Incidence of adverse reactions in high and low dose group were 9.09% and 7.27%, respectively, and there were differences between the two groups(P 0.05). Conclusion Low dose of simvastatin combined with fenofibrate has a good clinical effect in treatment of type 2 diabetes complicated with hyperlipidemia, and can be better control levels of blood lipid, which can reduce the metabolism burden of kidney and the incidence of adverse reactions.